blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3920969

EP3920969 - CONNEXIN 43 ANTIBODIES AND USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  12.11.2021
Database last updated on 19.10.2024
FormerThe international publication has been made
Status updated on  14.08.2020
Most recent event   Tooltip31.01.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Alamab Therapeutics, Inc.
302 Carnegie Center Boulevard
Princeton NJ 08542 / US
[2021/50]
Inventor(s)01 / ZHANG, Yanfeng
c/o AlaMab Therapeutics, Inc.
302 Carnegie Center Blvd.
Princeton, New Jersey 08542 / US
[N/P]
Former [2021/50]01 / ZHANG, Yanfeng
Princeton, New Jersey 08542 / US
Representative(s)Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[2021/50]
Application number, filing date20752507.204.02.2020
[2021/50]
WO2020US16606
Priority number, dateUS201962800869P04.02.2019         Original published format: US 201962800869 P
[2021/50]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020163353
Date:13.08.2020
Language:EN
[2020/33]
Type: A1 Application with search report 
No.:EP3920969
Date:15.12.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 13.08.2020 takes the place of the publication of the European patent application.
[2021/50]
Search report(s)International search report - published on:US13.08.2020
(Supplementary) European search report - dispatched on:EP02.11.2022
ClassificationIPC:C07K16/18, C07K16/28, C07K7/06
[2022/48]
CPC:
C07K16/28 (EP,US); A61K39/395 (IL); C07K16/18 (IL,KR);
A61P25/28 (EP,KR,US); A61P29/00 (US); C07K16/46 (IL);
C07K19/00 (IL); A61K2039/505 (EP,KR,US); C07K2317/33 (KR,US);
C07K2317/34 (EP,US); C07K2317/52 (EP); C07K2317/565 (US);
C07K2317/734 (EP); C07K2317/76 (US); C07K2317/90 (EP);
C07K2317/92 (EP,US) (-)
Former IPC [2021/50]A61K39/395, C07K16/18, C07K16/46, C07K19/00, C12N15/13, C12P21/08
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/50]
TitleGerman:CONNEXIN-43-ANTIKÖRPER UND VERWENDUNG DAVON[2021/50]
English:CONNEXIN 43 ANTIBODIES AND USE THEREOF[2021/50]
French:ANTICORPS DE CONNEXINE 43 ET LEUR UTILISATION[2021/50]
Entry into regional phase31.08.2021National basic fee paid 
31.08.2021Search fee paid 
31.08.2021Designation fee(s) paid 
31.08.2021Examination fee paid 
Examination procedure31.08.2021Examination requested  [2021/50]
02.06.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
21.04.2022Renewal fee patent year 03
23.02.2023Renewal fee patent year 04
31.01.2024Renewal fee patent year 05
Penalty fee
Additional fee for renewal fee
28.02.202203   M06   Fee paid on   21.04.2022
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI]WO2015027120  (JIANG JEAN X [US], et al) [X] 4-16 * paragraph [0008] - paragraph [0017]; claims 1-9 * [I] 1-3;
 [XI]WO2017147561  (UNIV TEXAS [US]) [X] 4-15 * examples 1-4; claims 1-62 * [I] 1-3;
 [XPA]WO2019195273  (ALAMAB THERAPEUTICS INC [US]) [XP] 4-16 * page 13, line 31 - page 17, line 15; examples 1-6; claims 1-15; sequences 1-18 * [A] 1-3;
 [A]  - MUSIL L S ET AL, "Multisubunit assembly of an integral plasma membrane channel protein, gap junction connexin43, occurs after exit from the ER", CELL, ELSEVIER, AMSTERDAM NL, vol. 74, no. 6, doi:10.1016/0092-8674(93)90728-9, ISSN 0092-8674, (19930924), pages 1065 - 1077, (19930924), XP027461977 [A] 1-16 * abstract *

DOI:   http://dx.doi.org/10.1016/0092-8674(93)90728-9
International search[A]US2011223204  (DUFT BRADFORD J [US], et al) [A] 1-10 * entire document *;
 [A]US2012214234  (TAKAMATSU TETSURO [JP], et al) [A] 1-10 * entire document *;
 [A]US2016177298  (GREEN COLIN RICHARD [NZ], et al) [A] 1-10 * entire document *;
 [A]US2016200812  (JIANG JEAN X [US], et al) [A] 1-10* entire document *;
 [A]US2016331805  (GREEN COLIN RICHARD [NZ], et al) [A] 1-10 * entire document *;
 [X]WO2017147561  (UNIV TEXAS [US]) [X] 4, 5, 7-9 * entire document *;
 [PX]WO2019195273  (ALAMAB THERAPEUTICS INC [US]) [PX] 1-10 * entire document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.